Brief: Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLL
16/01/2024 21:43
Jan 16 (Reuters) - Nurix Therapeutics Inc NRIX.O :
* NURIX THERAPEUTICS RECEIVES U.S. FDA FAST TRACK
DESIGNATION FOR
NX-5948 FOR THE TREATMENT OF RELAPSED OR REFRACTORY CLL AND SLL
* NURIX THERAPEUTICS - NX-5948 WAS WELL-TOLERATED ACROSS ALL
DOSES
TESTED WITH NO DOSE LIMITING TOXICITIES OR TREATMENT-RELATED
SERIOUS ADVERSE EVENTS
Source text for Eikon: ID:nGNX5YJjyv
Further company coverage: NRIX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nurix Therapeutics
See all newsNurix Therapeutics Q3 swings to profit on Roche collaboration
Brief: Nurix Extends Gilead Collaboration For Oncology Program
Commercialize Potential Best-In-Class Btk Degrader Bexobrutideg Across Malignant Hematology, Immunology And Neurology
Nurix Therapeutics Q2 revenue falls sharply, net loss widens; strikes up to $2.3 bln collab with Roche
U.S. RESEARCH ROUNDUP- Datadog, Jabil, Prologis